Skip to main navigation Skip to search Skip to main content

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

  • Lavinia Tan
  • , Chris Brown
  • , Antony Mersiades
  • , Chee Khoon Lee
  • , Thomas John
  • , Steven Kao
  • , Genni Newnham
  • , Kenneth O’Byrne
  • , Sagun Parakh
  • , Victoria Bray
  • , Kevin Jasas
  • , Sonia Yip
  • , Stephen Q. Wong
  • , Sarah Ftouni
  • , Jerick Guinto
  • , Sushma Chandrashekar
  • , Stephen Clarke
  • , Nick Pavlakis
  • , Martin R. Stockler
  • , Sarah Jane Dawson
  • Benjamin J. Solomon
    • Peter Maccallum Cancer Centre
    • University of Melbourne
    • The University of Sydney
    • St. George Hospital
    • Chris O'Brien Lifehouse
    • St. Vincent's Hospital Melbourne
    • Princess Alexandra Hospital
    • Austin Health
    • Sir Charles Gairdner Hospital
    • Royal North Shore Hospital

    Research output: Contribution to journal › Article › peer-review

    21 Citations (Scopus)

    Abstract

    In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor (EGFR) T790M mutation (n = 47) by modulating selective pressure on resistant clones. The primary endpoint is progression free-survival (PFS) rate at 12 months, and secondary endpoints include: feasibility of alternating therapy, overall response rate (ORR), overall survival (OS), and safety. The 12-month PFS rate is 38% (95% CI 27.5-55), not meeting the pre-specified primary endpoint. Serial circulating tumor DNA (ctDNA) analysis reveals decrease and clearance of the original activating EGFR and EGFR-T790M mutations which are prognostic of clinical outcomes. In 73% of participants, loss of T790M ctDNA is observed at progression and no participants have evidence of the EGFR C797S resistance mutation following the alternating regimen. These findings highlight the challenges of treatment strategies designed to modulate clonal evolution and the clinical importance of resistance mechanisms beyond suppression of selected genetic mutations in driving therapeutic escape to highly potent targeted therapies.
    Original languageEnglish
    Article number1823
    JournalNature Communications
    Volume15
    Issue number1
    DOIs
    Publication statusPublished - Dec 2024

    Bibliographical note

    Publisher Copyright:
    © The Author(s) 2024.

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE'. Together they form a unique fingerprint.

    Cite this